The 2025 conference was jointly organized by Hanoi Medical University Hospital, Binh Duong General Hospital, Da Nang General Hospital, Gia Lai General Hospital, and Ha Giang General Hospital in Tuyen Quang Province, representing the pinnacle of Vietnam’s public healthcare system. Dr. Zhang joined an elite panel of international experts, including Prof. Wu-Hsiu Chang from Show Chwan Healthcare System, Dr. Ching-Tsung Tseng from AIM (Asia’s leader in AI medical diagnostics), an

Benzodiazepines (Diazepam) and related Z-drugs (Zolpidem), henceforth referred to as BZDRs, are widely used for clinical treatment of insomnia and anxiety disorders. BZDRs act on GABA type A receptors to inhibit neurotransmitters. We previously demonstrated that prolonged clinical use of BZDRs exacerbates the risk of breast cancer (BRCA).

Natural killer (NK) cells are a critical component of the human innate immune system. As their name implies, NK cells possess the natural ability to detect and destroy virus-infected and malignant cells without prior sensitization or antigen-specific priming. This rapid response mechanism positions them as one of the body’s first lines of defense against disease.

γδ T cells represent a unique and powerful subset of T lymphocytes that combine features of both innate and adaptive immunity. Unlike the conventional αβ T cells that require antigen presentation via MHC molecules, γδ T cells recognize stress-induced ligands in an MHC-independent manner—making them highly effective against malignancies, infections, and even chronic inflammatory conditions.

JY BioMed is pleased to announce that, in collaboration with our clinical development partner YC Biotech, we have officially initiated preparations for a stem cell-based clinical trial targeting Alzheimer’s disease at Taipei Medical University. The trial protocol has been commissioned and is progressing steadily toward regulatory submission and formal IRB review.

JY BioMed today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its umbilical cord-derived mesenchymal stem cell (UC-MSC) program. The clearance, issued by the Center for Biologics Evaluation and Research (CBER), allows the company to proceed with a first-in-human study under IND number 031083.0.

JY BioMed Co., Ltd. and YC Biotech Co., Ltd. are pleased to announce the formal submission of a regenerative medicine clinical research proposal for Parkinson’s disease to the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospitals.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its dendritic cell-derived exosome platform. This DMF, assigned Number 041487, provides comprehensive manufacturing and quality control information for investigational use of exosomes obtained from human dendritic cells.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its dendritic cell-derived exosome platform. This DMF, assigned Number 041487, provides comprehensive manufacturing and quality control information for investigational use of exosomes obtained from human dendritic cells.

JY BioMed announced the expansion of its research collaboration with Taipei Medical University (TMU) to investigate the application of gamma delta T cells (γδT) in hepatocellular carcinoma (HCC), the most common form of liver cancer.

JY BioMed today announced the establishment of a targeted research collaboration with Taipei Medical University (TMU) to explore the potential of mesenchymal stem cells (MSCs) in addressing Parkinson’s disease, a leading neurodegenerative disorder worldwide.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its human umbilical cord-derived mesenchymal stem cell (UC-MSC)-derived exosome product. The DMF, assigned Number 041203, documents the manufacturing processes, quality controls, and storage protocols for Ji Yan Biomedical’s investigational exosome platform.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its umbilical cord-derived mesenchymal stem cell (UC-MSC) product. This filing supports the company’s efforts to align with international regulatory standards for cell-based research materials and investigational development.

JY BioMed announced today the submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA), detailing the manufacturing process, quality controls, and facility compliance for its unmodified gamma delta T cell (Vδ2+ γδT) platform.

JY BioMed announced its active participation in an international biomedical delegation to Japan aimed at fostering cross-border collaboration in regenerative medicine and precision healthcare.

JY BioMed announced the filing of a U.S. Provisional Patent Application for a novel method aimed at the optimized expansion and activation of gamma delta T (γδT) cells for immunotherapy applications.

JY BioMed today announced the initiation of a targeted research collaboration with Taipei Medical University (TMU) to advance preclinical development activities in glioblastoma with its gamma delta T cell (γδT) immunotherapy platform.

According to a market research report, approximately 19.05 million deaths worldwide were attributed to cardiovascular disease (CVD) in 2022. Data from the American Heart Association (AHA) indicates that the global vascular stent market is expected to reach $22.69 billion by 2030, with a compound annual growth rate (CAGR) exceeding 6.0%.

HeXun Biosciences and JY BioMed have signed an exclusive licensing agreement for “Human-Derived Umbilical Cord Mesenchymal Stem Cell Drug Production Technology.” Following the licensing of related production technology for human umbilical cord mesenchymal stem cells (UC-MSCs) to JY BioMed, both parties will collaborate to develop specific MSC-derived exosomes using specialized techniques and data.

HeXun Biosciences (6986), a company listed on the Emerging Stock Market, has recently reached a new milestone in its operations. HeXun has signed a "Mesenchymal Stem Cell Drug - Production Technology" licensing agreement with JY BioMed. HeXun will provide JY BioMed with its umbilical cord-derived mesenchymal stem cell (UC-MSC) culture technology and exosome production technology.